Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer

Cancer Immunology, Immunotherapy

Volumn 61, Issue 12, 2012, Pages 2227-2238

  Hannan, Raquibul ^a   Zhang, Huagang ^b   Wallecha, Anu ^c   Singh, Reshma ^c   Liu, Laibin ^b   Cohen, Patrice ^b   Alfieri, Alan ^b   Rothman, John ^c   Guha, Chandan ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ADVAXIS INC   (United States)

Author keywords

Immunotherapy; Listeria PSA vaccine; Prostate cancer; Radiation therapy

Indexed keywords

ADXS 31 142; CANCER VACCINE; CYTOKINE; GAMMA INTERFERON; LISTERIA MONOCYTOGENES PROSTATE SPECIFIC ANTIGEN VACCINE; TETRAMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BLOOD ANALYSIS; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SIZE; CANCER TISSUE; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; RADIATION DOSE; SPLEEN; TREATMENT RESPONSE;

ANIMALS; BACTERIAL VACCINES; CANCER VACCINES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; EPITOPES, T-LYMPHOCYTE; IMMUNOTHERAPY; INTERFERON-GAMMA; LISTERIA MONOCYTOGENES; MALE; MICE; MICE, INBRED C57BL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84870996402     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1257-x     Document Type: Article

References (66)

1. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67-74. doi: 10.1016/j.ijrobp.2007.06.054
2. Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA (2004) Radical prostatectomy, external beam radiotherapy \72 Gy, external beam radiotherapy[ or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58(1):25-33
3. Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML (2006) Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: Impact on prostate cancer specific survival. J Urol 175(2):547-551. doi: 10.1016/S0022-5347(05)00152-7
4. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostatecancer (an EORTC study): A phase III randomised trial. Lancet 360(9327):103-106
5. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292(7):821-827. doi:10.1001/jama.292.7.821
6. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411-422. doi:10.1056/NEJMoa1001294
7. Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S (2012) Current vaccination strategies for prostate cancer. Eur Urol 61(2):290-306. doi:10.1016/j.eururo. 2011.09.020
8. Demaria S, Bhardwaj N, McBride WH, Formenti SC (2005) Combining radiotherapy and immunotherapy: A revived partnership. Int J Radiat Oncol Biol Phys 63(3):655-666. doi:10.1016/ j.ijrobp.2005.06.032
9. Hodge JW, Guha C, Neefjes J, Gulley JL (2008) Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) 22 ):1064-1070 (discussion 1075, 1080-1061, 1084
10. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviralbased PSA-targeted immunotherapy in metastatic castrationresistant prostate cancer. J Clin Oncol 28(7):1099-1105. doi: 10.1200/JCO.2009.25.0597
11. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N (2000) Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191(3):423-434
12. Shimamura H, Sunamura M, Tsuchihara K, Egawa S, Takeda K, Matsuno S (2005) Irradiated pancreatic cancer cells undergo both apoptosis and necrosis, and could be phagocytized by dendritic cells. Eur Surg Res 37(4):228-234. doi:10.1159/000087868
13. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13(9):1050-1059. doi:10.1038/nm1622
14. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, Zitvogel L, Kroemer G (2007) Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 14(10):1848-1850. doi:10.1038/sj.cdd.4402201
15. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54-61. doi:10.1038/nm1523
16. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203(5):1259-1271. doi:10.1084/jem.20052494
17. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW (2003) Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 170(12):6338-6347
18. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW (2004) Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64(21):7985-7994. doi:10.1158/0008-5472.CAN-04-1525
19. Boehm U, Klamp T, Groot M, Howard JC (1997) Cellular responses to interferon-gamma. Annu Rev Immunol 15:749-795. doi:10.1146/annurev.immunol.15.1. 749
20. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL (2011) The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 71(7):2488-2496. doi: 10.1158/0008-5472.CAN-10-2820
21. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM (2005) Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174(12):7516-7523
22. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM (2008) Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 180(5):3132-3139
23. Kaminski JM, Summers JB, Ward MB, Huber MR, Minev B (2003) Immunotherapy and prostate cancer. Cancer Treat Rev 29(3):199-209
24. CatalonaWJ(1996) Clinical utility ofmeasurements of free and total prostate-specific antigen (PSA): A review. Prostate Suppl 7:64-69
25. Kantoff PW, Talcott JA (1994) The prostate specific antigen. Its use as a tumor marker for prostate cancer. Hematol Oncol Clin North Am 8(3):555-572
26. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY (1997) In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 89(4):293-300
27. Xue BH, Zhang Y, Sosman JA, Peace DJ (1997) Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 30(2):73-78
28. Elzey BD, Siemens DR, Ratliff TL, Lubaroff DM (2001) Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer 94(6):842-849
29. Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, Gritz L, Panicali D, Kantor JA (1995) A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a non-human primate. Int J Cancer 63(2):231-237
30. Pavlenko M, Roos AK, Leder C, Hansson LO, Kiessling R, Levitskaya E, Pisa P (2004) Comparison of PSA-specific CD8? CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins. Cancer Immunol Immunother 53(12):1085-1092
31. Shahabi V, Reyes-Reyes M, Wallecha A, Rivera S, Paterson Y, Maciag P (2008) Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother 57(9):1301-1313. doi:10.1007/s00262-008-0463-z
32. Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Menard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W (2005) Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11(9):3353-3362. doi:10.1158/1078-0432.CCR-04-2062
33. Wallecha A, Maciag PC, Rivera S, Paterson Y, Shahabi V (2009) Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin Vaccine Immunol 16(1):96-103. doi:10.1128/CVI.00274-08
34. Barry RA, Bouwer HG, Portnoy DA, Hinrichs DJ (1992) Pathogenicity and immunogenicity of Listeria monocytogenes smallplaque mutants defective for intracellular growth and cell-to-cell spread. Infect Immun 60(4):1625-1632
35. Tilney LG, Portnoy DA (1989) Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes. J Cell Biol 109(4 Pt 1):1597-1608
36. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM (1993) Development of TH1 CD4? T cells through IL-12 produced by Listeria-induced macrophages. Science (New York, NY 260 (5107):547-549
37. Ikonomidis G, Paterson Y, Kos FJ, Portnoy DA (1994) Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes. J Exp Med 180(6):2209-2218
38. Beatty GL, Paterson Y (2001) Regulation of tumor growth by IFN-gamma in cancer immunotherapy. Immunol Res 24(2):201-210. doi:10.1385/IR:24:2:201
39. Beck-Engeser GB, Monach PA, Mumberg D, Yang F, Wanderling S, Schreiber K, Espinosa R III, Le Beau MM, Meredith SC, Schreiber H (2001) Point mutation in essential genes with loss or mutation of the second allele: Relevance to the retention of tumorspecific antigens. J Exp Med 194(3):285-300
40. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y (2001) Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 167(11):6471-6479
41. Hussain SF, Paterson Y (2004) CD4? CD25? regulatory T cells that secrete TGFbeta and IL-10 are preferentially induced by a vaccine vector. J Immunother 27(5):339-346
42. Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y (2008) Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 68(19):8066-8075. doi:10.1158/0008-5472.CAN-08- 0287
43. Singh R, Dominiecki ME, Jaffee EM, Paterson Y (2005) Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J Immunol 175(6): 3663-3673
44. Singh R, Paterson Y (2007) In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines. Cancer Immunol Immunother 56(6):927-938. doi:10.1007/s00262-006-0237-4
45. Chakravarty PK, Guha C, Alfieri A, Beri V, Niazova Z, Deb NJ, Fan Z, Thomas EK, Vikram B (2006) Flt3L therapy following localized tumor irradiation generates long-term protective immune response in metastatic lung cancer: Its implication in designing a vaccination strategy. Oncology 70(4):245-254. doi: 10.1159/000096288
46. Meng Y, Carpentier AF, Chen L, Boisserie G, Simon JM, Mazeron JJ, Delattre JY (2005) Successful combination of local CpGODN and radiotherapy in malignant glioma. Int J Cancer 116(6):992-997. doi:10.1002/ijc.21131
47. Kim KW, Kim SH, Shin JG, Kim GS, Son YO, Park SW, Kwon BH, Kim DW, Lee CH, Sol MY, Jeong MH, Chung BS, Kang CD (2004) Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity. Int J Cancer 109(5):685-690. doi:10.1002/ijc.20036
48. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW (2004) External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccinemediated T-cell killing. Cancer Res 64(12):4328-4337. doi: 10.1158/0008-5472.CAN-04-0073
49. Tseng CW, Trimble C, Zeng Q, Monie A, Alvarez RD, Huh WK, Hoory T, Wang MC, Hung CF, Wu TC (2009) Low-dose radiation enhances therapeutic HPV DNA vaccination in tumorbearing hosts. Cancer Immunol Immunother 58(5):737-748. doi: 10.1007/s00262-008-0596-0
50. Pavlenko M, Leder C, Roos AK, Levitsky V, Pisa P (2005) Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA. Prostate 64(1):50-59. doi:10.1002/pros. 20221
51. Shang XY, Chen HS, Zhang HG, Pang XW, Qiao H, Peng JR, Qin LL, Fei R, Mei MH, Leng XS, Gnjatic S, Ritter G, Simpson AJ, Old LJ, Chen WF (2004) The spontaneous CD8? T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin Cancer Res 10(20):6946-6955
52. Dasu A (2007) Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol) 19(5):289-301. doi:10.1016/j.clon.2007.02.007
53. King CR, Fowler JF (2001) A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys 51(1):213-214
54. Fowler J, Chappell R, Ritter M (2001) Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50(4):1021-1031
55. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I (2000) Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18(23): 3904-391156.
56. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16):3670-3679. doi:10.1002/cncr. 24429
57. Neeson P, Pan ZK, Paterson Y (2008) Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma. Cancer Immunol Immunother 57(4):493-505. doi:10.1007/ s00262-007-0388-y
58. Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J (2002) Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53(2):109-117. doi:10.1002/pros.10130
59. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109(3):409-417. doi:10.1172/JCI14364
60. Williams SA, Xu Y, De Marzo AM, Isaacs JT, Denmeade SR (2010) Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/ KLK2 double transgenic mice. Prostate 70(7):788-796. doi: 10.1002/pros.21111
61. Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie XJ, Yan J, Foster R, Pistenmaa D, Perkins A, Cooley S, Timmerman R (2011) Phase I dose-escalation study of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer. J Clin Oncol 29(15):2020-2026. doi:10.1200/JCO.2010.31.4377
62. Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS (2004) High dose rate brachytherapy asprostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 171(3):1098-1104. doi: 10.1097/01.ju.0000113299.34404.22
63. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567-578. doi:10.1056/ NEJMoa053422
64. D'Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW (2008) Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol 26(18):2979-2983. doi:10.1200/JCO.2007.15.9699
65. Maciag PC, Radulovic S, Rothman J (2009) The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 27(30):3975-3983. doi:10.1016/j.vaccine. 2009.04.041
66. Radulovic S, Brankovic-Magic M, Malisic E, Jankovic R, Dobricic J, Plesinac-Karapandzic V, Maciag PC, Rothman J (2009) Therapeutic cancer vaccines in cervical cancer: Phase I study of Lovaxin-C. J BUON 14(Suppl 1):S165-S168